Table 3.
Rescue medication use during the AOM 400 maintenance phase
| Medication | Enrollment source | Number of patients | Number (%) taking rescue medication | Duration (days)a | ||
|---|---|---|---|---|---|---|
| Mean | SD | Median | ||||
| Lithium | De novo | 379 | 28 (7.4) | 147.9 | 101.8 | 131.5 |
| Rollover | 85 | 0 | – | – | – | |
| Total | 464 | 28 (6.0) | 147.9 | 101.8 | 131.5 | |
| Valproate | De novo | 379 | 35 (9.2) | 114.5 | 96.6 | 100 |
| Rollover | 85 | 1 (1.2) | 84.0 | – | 84.0 | |
| Total | 464 | 36 (7.8) | 113.7 | 95.4 | 92.0 | |
Rescue medication (lithium [immediate or controlled release] or valproate [immediate or extended release]) was recommended for patients not meeting stability criteria. Only one type of rescue medication was permitted at a time. Patients meeting stability criteria were not eligible for rescue medication
AOM 400 aripiprazole once-monthly 400 mg, SD standard deviation
aCalculated for patients receiving AOM 400 during maintenance phase who took rescue medication during maintenance phase